San Francisco, 26 March 2027: The Report Canine Atopic Dermatitis Market Size, Share & Trends Analysis Report By Product, By Mode Of Administration (Topical, Oral), By Distribution Channel (Retail, E-commerce), By Region, And Segment Forecasts, 2020 - 2027

The global canine atopic dermatitis market size is expected to reach USD 1.8 billion by 2027, expanding at a CAGR of 9.0% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of the disease and growing companion ownership are the key factors driving the market growth.

Growing concern among pet owners regarding their pet’s health is further propelling the market growth. According to American Academy of Physician Assistants (AAPA), U.S. pet owners spent around USD 7.4 billion on pet care in 2017 whereas, Europe spent around USD 6.1 billion. The anticipated rise in dog ownership is expected to increase the demand for better treatment facilities.

According to The American Pet Products Association report 2018, veterinary care spending increased by 7% from USD 15.95 billion in 2016 to USD 17.07 billion in 2017. An increase in the number of veterinary clinic visits is further boosting the canine atopic dermatitis market growth. According to the American Veterinary Medical Association (AVMA) report, as of 2018, around 70% dog owners usually go to veterinary hospitals or clinics for the routine check-up of their pets. These aforementioned factors are expected to fuel the growth of the canine atopic dermatitis treatment market over the forecast period.

Increasing incidences of atopic dermatitis in dogs fueled by air pollution and allergens is the key driver for this market. The most common symptoms associated with atopic dermatitis are scratching, itching, foul odor, loss of hair, scaly skin, etc. The breeds found to be most susceptible to this canine atopic dermatitis are Golden Retriever, German Shepherd, Labrador, andPug. Rapid industrialization in the developing and developed countries is anticipated to further propel the market growth.

According to the American College of Veterinary Dermatology (ACVD) report, around 10% to 15% of dogs suffered from this canine atopic dermatitis in 2017. The x of this disease is not completely understood yet, though genetic abnormalities are reported to be one of the major reasons behind it. According to a study by the American Journal Of Veterinary Research, the risk to develop canine atopic dermatitis in golden retrievers was around 50% in the U.K. due to geographic variation, which is expected to bolster the revenue in the coming years.

Request sample report of Canine Atopic Dermatitis Market@ https://www.grandviewresearch.com/industry-analysis/canine-atopic-dermatitis-treatment-market/request/rs1

The increasing number of veterinary practitioners is one of the major factors driving the demand for this market. According to the American Veterinary Medical Association, a total of 113,394 veterinary practitioners were present in the U.S. in 2018 compared to 110,531 in 2017. Moreover, increasing number of veterinary hospitals and clinics is propelling the market growth.

Furthermore, increasing R&D investment by the key industry players, product launches, and strong drug pipeline are also expected to contribute significantly to the market growth. For instance, Kindred Biosciences, Inc. reportedly has 4 monoclonal antibodies in their pipeline for canine atopic dermatitis, which is expected to launch in the coming five years. In 2016, Zoetis launched Cytopoint, a monoclonal antibody which became a blockbuster drug in 2018.

The rising demand for pet insurance and increasing concern among pet owners are anticipated to exhibit a positive impact on the market in the coming years. Moreover, stringent regulations by the Food and Drug Administration (FDA) and other regulatory bodies in order to reduce the off label usage of human drugs in animals is boosting the market growth.

The market is consolidated in nature. Zoetis held more than 50% of the revenue share as of 2018. The two main drugs of canine atopic dermatitis namely Apoquel and Cytopoint generated sizeable revenue in 2018. With around 20% growth in 2018, these drugs are poised to represent this market with significant growth opportunities in the next few years.

Other key players in the market include Elanco, Virbac, and Toray Industries. Extensive product pipeline by some new industry players such as Kindred Biosciences, AB Science is expected to bolster the market in the coming years. Strategies such as mergers, acquisitions, regional expansion, and launch of new products are being adopted by the players to maintain their share. For instance, in February 2020, Zoetis launched its blockbuster drug Apoquel in China to gain regional revenue share.